Thursday 7 May, 2026
Introduction: Drug development in oncology faces high failure rates and significant costs, due to methodological and operational challenges. Modeling and…
Read moreAbstracts
Mechanistic Modeling of Radiation-Induced Immune Responses in Normal Lung Tissue
Thursday 7 May, 2026
Objectives Radiation therapy (RT) is a standard treatment for thoracic cancers such as lung cancer and lymphoma. However, exposure of…
Read moreQUANTIFICATION OF INDIVIDUAL Î’-CELL FUNCTION AND INSULIN SENSITIVITY: TOWARDS PERSONALISED LIFESTYLE AND MEDICINE TREATMENT
Thursday 7 May, 2026
Objectives Type 2 diabetes mellitus (T2DM) is a major global health challenge, marked by insulin resistance and progressive dysfunction of…
Read moremlxModelFinder: Machine Learning–Enhanced Search for Efficient Structural Model Discovery in Monolix
Thursday 7 May, 2026
Introduction: Automated structural model building has previously been explored, including a systematic comparison of six algorithms across simulation studies and…
Read moreA QSP Model to Describe the Time Course of Tolvaptan’s Diuretic Effect in Heart Failure Patients with Fluid Overload
Thursday 7 May, 2026
Objectives: In fluid overloaded heart failure, relieving congestion while minimizing electrolyte disturbances is critical. Tolvaptan, a vasopressin V2 receptor antagonist,…
Read moreUSING PBPK MODELLING TO IDENTIFY PHYSIOLOGICAL CHANGES INDUCED BY CLF065, A GLP 2 RECEPTOR AGONIST, ON THE PHARMACOKINETICS OF ACYCLOVIR AND TO PREDICT POTENTIAL DRUG–DRUG INTERACTIONS WITH OTHER COMPOUNDS
Thursday 7 May, 2026
Introduction: CLF065 is a long-acting glucagon-like peptide 2 (GLP 2) receptor agonist in development by Calibr–Skaggs for the treatment of…
Read moreEVALUATION OF MODEL SELECTION AND AVERAGING ALGORITHMS FOR MODEL-INFORMED PRECISION DOSING OF GENTAMICIN IN NEONATES
Thursday 7 May, 2026
Objectives: Gentamicin is widely used to treat bacterial infections, including those in neonatal patients. Elevated trough concentrations frequently lead to…
Read moreBridging insights: Quantitative pharmacology-biostatics collaboration of Population PKPD and Bayesian Logistic Regression Enabling Dosage Selection in Early-Phase Oncology
Thursday 7 May, 2026
Objective: Traditional oncology dose-finding trials primarily focus on dose-limiting toxicity (DLT) data to guide dose-escalation decisions. Bayesian Logistic Regression Models…
Read morePredicting Mucosal Healing in IBD: The Interplay of Platelet Levels and Infliximab Pharmacokinetics
Thursday 7 May, 2026
Introduction: Patients with inflammatory bowel disease (IBD) often face challenges in maintaining stable disease without complications. Mucosal healing (MH), assessed…
Read morePRIOR-FITTED AMORTIZED GENERATIVE NEURAL NETWORKS MODELS FOR POPULATION PHARMACOKINETICS
Thursday 7 May, 2026
Objectives Nonlinear mixed-effects (NLME) modelling [1] is the established population approach for pharmacokinetics (PK) and has been highly successful in…
Read more